Together, we have the power to create change
Through Cancer Grand Challenges, Cancer Research UK is building a global network of funders and partners who share our ambitions to make radical progress against cancer.
Together, we can galvanise the world’s scientific community – freeing them from constraints to inspire their scientific creativity.
We proudly recognise and honour the individuals and organisations whose generosity demonstrates a steadfast commitment to our mission.
Click on the logos and names below to find out more about our partners and donors.
Asociación Española Contra el Cáncer
The Spanish Association Against Cancer has been the reference entity in the fight against cancer for 69 years. It dedicates its efforts to showing the reality of cancer in Spain, detecting areas for improvement and launching a process of social transformation that allows them to be corrected in order to eliminate inequities in Spain. Being by the side of people is in its DNA, so its work is also aimed at helping prevent cancer; be with them and their families throughout the disease process from diagnosis to the survivor stage and improve their future by promoting cancer research. In this sense, through its Scientific Foundation, the Association brings together the social demand for cancer research, financing quality scientific cancer research programs through public competition. Today, it is the social and private entity that allocates the most funds to cancer research with over 92 million euros in 525 projects, with over 1,000 researchers engaged.
The Association integrates patients, relatives, volunteers and professionals who work together to prevent, raise awareness, accompany affected people and finance cancer research projects that will allow better diagnosis and treatment of cancer. Structured in 52 Provincial Headquarters, and present in more than 2,000 Spanish towns, it has over 30,000 volunteers, almost 600,000 members and 1,160 professionals.
During 2021, the Spanish Association Against Cancer has provided free services for 136,000 people affected by cancer.
KWF Dutch Cancer Society
Cancer Grand Challenges PRECISION team, led by Professor Jelle Wesseling, is jointly funded by Cancer Research UK and the Dutch Cancer Society.
For more than 70 years, the Dutch Cancer Society has been committed to supporting innovative research and policy work to bring about an end to cancer. This nationwide organisation receives no government funding. Instead, it relies on its 1m donors and 100,000 volunteers and joins forces with international stakeholders to achieve its aim – a better life, with and without cancer.
The Dutch Cancer Society’s partnership is supporting the work of PRECISION – an expert team of pathologists, oncologists, biologists and geneticists from the Netherlands, the UK and the US. The team is investigating ductal carcinoma in situ (DCIS), a condition that can sometimes develop into breast cancer. By developing new ways to distinguish whether a woman’s DCIS will or won’t develop into breast cancer, the team hopes to spare thousands of people from undergoing unnecessary treatment.
We were inspired by the ambition to bring together the best minds to find solutions to the most urgent questions in cancer research.
Fred Falkenburg, Director of the Dutch Cancer Society (KWF)
The Mark Foundation for Cancer Research supports two outstanding Cancer Grand Challenges teams.
The Mark Foundation first teamed up with Cancer Research UK in 2019 to jointly fund the SPECIFICANCER team. This world-class team from the US, the UK, and the Netherlands is led by Professor Steven Elledge. In June 2022, The Mark Foundation partnered with Cancer Research UK and the National Cancer Institute to support the NexTGen team, led by Professor Catherine Bollard and Dr. Martin Pule. The multi-million-pound gifts from this New York-based philanthropic group are its largest commitment to a UK organisation to date.
The Mark Foundation for Cancer Research actively partners with scientists, research institutions, and philanthropic organisations around the world to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. Founded in 2017, The Mark Foundation recently received an additional $500 million commitment to continue funding innovative basic, translational, and clinical cancer research, including drug discovery. The Mark Foundation also has a robust and growing portfolio of investments in oncology companies developing novel therapeutics and diagnostics.
"The ambition, scale of funding, and rigorous selection process for these projects offered The Mark Foundation an ideal opportunity to support the acceleration of critical cancer research."
Ryan Schoenfeld, PhD, Chief Executive Officer of The Mark Foundation for Cancer Research
We’re proud to support these remarkable Cancer Grand Challenge global teams in their efforts to solve extremely complex challenges facing cancer patients.”
Raymond N. DuBois, MD, PhD, Executive Chairman of The Mark Foundation for Cancer Research
Founder of IK Investment Partners Limited. Bjorn is also Chairman of IKARE as well as director of and member of the executive committee of the Swedish Chamber of Commerce in London. He was Chief Executive of IK Investment Partners since it started in 1989 until 2010 and Chairman until 2017. Previous work experience includes 12 years with the Esselte Group (1976-1988) in Sweden, the UK and the USA as well as two years at Gulf Oil (1972-74). Mr Saven holds an MBA from Harvard Business School (1976) and a degree from Stockholm School of Economics (1972).
He has held various non-executive directorships including Nordea Bank, Orkla, Alfa-Laval (deputy Chairman), Konecranes (Chairman) and Vattenfall. He was deputy chairman of the Royal Swedish Academy of Engineering Sciences.
Currently he serves as a trustee at the National Portrait Gallery in London, at Tommy’s (the UK pre-natal care charity) and at the Heart/Lung Foundation of Sweden as well as on the European Spallation Source executive advisory board at Lund.
Bjorn Saven holds honorary doctorates from the Stockholm School of Economics and Business (2010), the Swedish School of Economics and Business in Helsinki (1999) as well as from the Institute of Technology at Lund University (2013).
Cancer Ground Challenge is a strong mission to save and improve many lives for the future. It is a great endeavour to join.
David Caplan is a Partner and the General Counsel at Atairos, an independent strategic investment company focused on supporting growth-oriented businesses . David joined Atairos after serving for over 20 years as a Partner at the law firm of Davis Polk & Wardwell LLP, where he served as the head of the firm’s Global Mergers & Acquisitions practice.
At Davis Polk, David advised clients on mergers and acquisitions, joint ventures, and securities law and corporate governance matters, and led client relationships across a wide range of industries.
David is a member of the Board of Directors of Ardan/Westcor Land Title Insurance Company, Ocean Outdoor and The Orogen Group. David was previously a member of the Board of Trustees of Playwrights Horizons, one of the country’s leading not-for-profit theaters.
David is a graduate of Princeton University and Harvard Law School.
Cancer affects all of us. Cancer Grand Challenge’s mission to tackle fundamental cancer-related challenges by supporting large, global, multi-disciplinary teams comprised of the world’s leading researchers is compelling and—hopefully—life saving. I am honored to support this initiative in its critical, innovative work.
David L. Caplan
Partner & General Counsel